000			02096na a2200253 4500
999			_c9618 _d9618
003			PC9618
005			20210625062810.0
008			130622s2013 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aCiruelos Gil, Eva María _91082 _eOncología Médica
245	0	0	_aShotgun proteomics of archival triple-negative breast cancer samples. _h[artículo]
260			_bProteomics Clinical Applications, _c2013
300			_a7(3-4):283-91.
500			_aFormato Vancouver: Gámez-Pozo A, Ferrer NI, Ciruelos E, López-Vacas R, Martínez FG, Espinosa E et al. Shotgun proteomics of archival triple-negative breast cancer samples. Proteomics Clin Appl. 2013 Apr;7(3-4):283-91.
501			_aPMID: 23436753
504			_aContiene 55 referencias
520			_aPurpose: Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers, and has a worse prognosis compared with hormone receptor-positive disease. Its unfavorable outcome and the lack of hormonal receptors determine the use of adjuvant chemotherapy as part of the standard treatment for these tumors, although several studies have documented that the current standard combination chemotherapy is suboptimal. Therefore, a new functional taxonomy of breast cancer and new targets for therapeutic development are urgently needed. Experimental design: In this study, we have analyzed the proteome of TNBC applying a high-throughput proteomics approach to routinely archived formalin-fixed, paraffin-embedded tumor tissues. Results: We have been able to identify and quantify more than 1000 protein groups. Some of these proteins are of outstanding interest in the biology and clinical management of this disease, such as CD44 and PARP1. Moreover, we have characterized some signaling pathways that could be related to TNBC genesis and development. Conclusion and clinical relevance: Our results open up new avenues for the use of proteomics technologies in clinically relevant studies using archival samples. Shotgun LC-MS/MS studies could serve to discover new biomarkers and may provide clues to the genesis of TNBC and underlying molecular alterations.
710			_9303 _aServicio de Oncología Médica
710			_9625 _aInstituto de Investigación imas12
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/9/pc9618.pdf _ySolicitar documento
942			_n0 _2ddc _cART